BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1099 related articles for article (PubMed ID: 30049563)

  • 1. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice.
    Lee SB; Yu JH; Park H; Kim HJ; Park SH; Chae BJ; Youn HJ; Jung SY; Kim EK; Jung YS; Son BH
    Asian J Surg; 2019 Jan; 42(1):314-319. PubMed ID: 30049563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Axillary management in breast cancer: The French practice versus recommendations in the post-2011 era].
    Clavier A; Cornou C; Capmas P; Bats AS; Bensaid C; Nos C; Lécuru F; Ngô C
    J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):451-8. PubMed ID: 26989008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
    Mann JM; Wu X; Christos P; Nagar H
    Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands.
    Ho VK; van der Heiden-van der Loo M; Rutgers EJ; van Diest PJ; Hobbelink MG; Tjan-Heijnen VC; Dirx MJ; Reedijk AM; van Dijck JA; van de Poll-Franse LV; Schaapveld M; Peeters PH
    Eur J Cancer; 2008 Mar; 44(5):683-91. PubMed ID: 18314328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.
    van der Heiden-van der Loo M; de Munck L; Sonke GS; van Dalen T; van Diest PJ; van den Bongard HJ; Peeters PH; Rutgers EJ
    Eur J Cancer; 2015 May; 51(8):915-21. PubMed ID: 25857549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.
    Jones JL; Zabicki K; Christian RL; Gadd MA; Hughes KS; Lesnikoski BA; Rhei E; Specht MC; Dominguez FJ; Smith BL
    Am J Surg; 2005 Oct; 190(4):517-20. PubMed ID: 16164912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
    Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?
    Osorio-Silla I; Gómez Valdazo A; Sánchez Méndez JI; York E; Díaz-Almirón M; Gómez Ramírez J; Rivas Fidalgo S; Oliver JM; Álvarez CM; Hardisson D; Díaz Miguel M; Lobo F; Díaz Domínguez J
    Ann R Coll Surg Engl; 2019 Mar; 101(3):186-192. PubMed ID: 30421628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.
    Frasson AL; Resende HM; Lichtenfels M; Barbosa F; de Souza ABA; Miranda I; Falcone AB
    J Surg Oncol; 2020 Nov; 122(6):1247-1251. PubMed ID: 33045117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists.
    Simons JM; Maaskant-Braat AJG; Luiten EJT; Leidenius MHK; van Nijnatten TJA; Boelens PG; Koppert LB; van der Pol CC; van de Velde CJH; Audisio RA; Smidt ML
    Eur J Surg Oncol; 2020 Jan; 46(1):53-58. PubMed ID: 31434617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
    Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
    Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.